Lumena developed a drug for the treatment of Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), two life-threatening pediatric liver diseases. If left untreated, these conditions can lead to liver failure and inflict life-altering symptoms including stunted growth and severe, non-stop itching. RiverVest was a founder of the company.

Acquired by Shire in June 2014, then sold to Mirum Pharmaceuticals, Inc. in 2019.